Notably, for patients with heavily pretreated HER2+ CRC and BTC (4 received 15 mg/kg and 1 received 10 mg/kg), the ORR was 40% (2/5), and the DCR was 80% (4/5). This evidence concerns the gene ERBB2 and colorectal carcinoma.